Deep Genomics is a healthcare company that is using artificial intelligence to build a new universe of life-saving genetic therapies.
Deep Genomics develops an artificial intelligence-powered discovery platform that supports geneticists, molecular biologists, chemists, toxicologists, and drug developers in the identification and development of genetic medicines.
Deep Genomics was founded in 2014 by Brendan Frey and is based in Toronto, Ontario, Canada.
Deep Genomics develops genetic medicines using our biologically accurate artificial intelligence technology, with a focus on the preclinical development of oligonucleotide therapies
Deep Genomics' platform incorporates the most advanced biological knowledge, is driven by the most powerful automation technologies, and is built using proprietary as well as public datasets. Our work has appeared in Science, Nature, Nature Genetics, Nature Medicine, Nature Methods, Proceedings of the IEEE, NIPS, Bioinformatics, RECOMB and ISMB.
Deep Genomics is backed by investors including Khosla Ventures, True Ventures, Bloomberg Beta and others.